Yahoo Finance8d
Virax Biolabs Presents Data on T-Cell Dysfunction in Post-acute Infection Syndromes at the 19th World Immune Regulation Meeting
LONDON, March 13, 2025 /PRNewswire/ -- Virax Biolabs Group Limited ("Virax" or the "Company") (Nasdaq: VRAX), an innovative biotechnology company focused on the detection of immune responses and ...
Yahoo Finance25d
EXCLUSIVE: Virax Biolabs Says Its Tech Fits RFK Jr.'s HHS Goals On Vaccine Transparency
On Thursday, Virax Biolabs Group Limited (NASDAQ:VRAX) said it supports the U.S. Department of Health and Human Services’ focus on vaccine efficacy transparency, emphasizing the need for ...
Investing8d
Virax Biolabs shares T-Cell dysfunction findings
LONDON - Virax Biolabs Group Limited (NASDAQ:VRAX), a micro-cap biotechnology company with a market value of $6.39 million specializing in immune response detection and viral disease diagnosis ...
ETF Daily News22d
Short Interest in Virax Biolabs Group Limited (NASDAQ:VRAX) Expands By 205.8%
An institutional investor recently bought a new position in Virax Biolabs Group stock. XTX Topco Ltd purchased a new position in shares of Virax Biolabs Group Limited (NASDAQ:VRAX – Free Report ...
Benzinga.com24d
EXCLUSIVE: Virax Biolabs Says Its Tech Fits RFK Jr.'s HHS Goals On Vaccine Transparency
Virax Biolabs' technology supports vaccine efficacy assessments and long-term immune protection monitoring. The company collaborates with vaccine developers to enhance transparency and advance ...